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Nuclear medicine is expanding into new areas of clinical 
practice, of which positron emission tomography (PET) is 
an example. As in new treatments with labelled monoclonal 
antibodies, especially for lymphoma, the wide introduction 
of PET into health care in South Africa presents benefits and 
challenges to patients, doctors, and funders.
   PET is an imaging modality that has been available in 
specialised centres in the developed world since the 1970s. It 
was initially used as a research tool to image organ function 
in vivo. The development of the radiopharmaceutical F-18-
fluorodeoxyglucose (FDG), a glucose analogue taken up avidly 
by the majority of tumours, has resulted in PET now being 
used routinely in the management of many cancer patients 
in centres with access to it. There has been rapid growth of 
PET in the developed world and it has also been introduced 
into developing countries, including Egypt. We welcome 
government initiatives to establish PET imaging in South 
Africa, as evidenced by the provision of cyclotrons in Gauteng 
and Cape Town.
The principle of PET
PET is a functional imaging method that is sensitive and 
specific and allows the metabolic mapping of normal 
processes and disease in vivo.  Tracer amounts of radiolabelled 
compounds are injected; these are handled biochemically in 
a manner similar to that of their normal or ‘cold’ biochemical 
equivalents. Positron-emitting isotopes such as F-18, C-11, N-13, 
and O-15 are incorporated into organic compounds without 
altering their properties.  The flexible chemistry afforded 
by PET radionuclides provides a vast range of radiotracers 
with the potential to investigate physiological processes and 
tumour biology. There is an extensive literature on the use of 
radiolabelled carbohydrates, amino acids, neurotransmitters 
and drugs, among others. Imaging of glucose utilisation with 
FDG is an established, clinically useful tool. There is a rapidly 
growing literature on the imaging of cellular proliferation, 
hypoxia, neo-angiogenesis and apoptosis.1
   After injection of the radiopharmaceutical the radionuclide 
incorporated in the molecule undergoes decay in vivo with 
the emission of a positron. The positron travels a short 
distance within tissue before interacting with an electron, 
undergoing annihilation and releasing two gamma rays in 
opposite directions. A ring of detectors, which determine the 
biodistribution of the radiolabelled compound, detects these 
gamma rays leaving the patient.  This is represented as a three-
dimensional image, similar to those of computed tomography 
(CT) or magnetic resonance imaging (MRI).
PET/CT
PET and CT scanners have recently been combined into a single 
hybrid imaging device that performs the two separate scans 
in the same imaging session, allowing accurate fusion of the 
two image types. PET/CT combines the strengths of the two 
imaging modalities, namely the anatomical detail of CT and 
the functional information of PET. The enhanced localisation of 
PET lesions using CT improves the accuracy of interpretation of 
the study.2 The advantages of combining PET and CT include: 
(i) superior lesion localisation from accurate anatomical/
functional registration with fewer motion artefacts; (ii) better 
distinction between physiological uptake and pathological 
uptake; (iii) consolidation of a patient's imaging studies; and 
(iv) significantly shorter scan time by using CT for attenuation 
correction – this enhances patient comfort and minimises 
problems with claustrophobia.
   PET is a nuclear medicine imaging procedure that uses 
open sources of radioactivity, and 18F-FDG and other 
positron-emitting radiopharmaceuticals are not sophisticated 
‘contrast agents’. The introduction of the combined technique 
has resulted in a debate about the respective roles of the 
two specialties, nuclear medicine and radiology, although 
recommendations exist in this regard.3
Clinical indications
While there are established indications in neurology and 
cardiology, the vast majority of the PET studies performed 
today are in the field of oncology. PET provides unique 
information to characterise lesions, stage and restage cancers, 
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predict patient prognosis, and monitor the effectiveness of 
cancer therapies. PET has a particular role in tumours of the 
head and neck, lung, oesophagus, breast and colon, as well 
as in lymphoma and melanoma. Radiation therapy treatment 
planning and infection imaging (fever of unknown origin) 
are promising areas for its utilisation in the future.4,5 It is 
also useful in the management of AIDS patients with central 
nervous system (CNS) lesions since high FDG uptake probably 
represents a malignant process, which should be biopsied for 
confirmation rather than treated presumptively as infection.6
   The diagnostic accuracy and cost-effectiveness of any new 
method depends in part on the prevalence of the disease 
in the population under investigation. Therefore a simple 
extrapolation of data from other populations may not be 
accurate for the majority of the South African population 
and must be taken into account in considering and adapting 
the clinical utility of the technique in our country.  To avoid 
inappropriate and costly utilisation of the modality, the clinical 
indications should be limited to those already scientifically 
accepted. The only acceptable exception is in conducting 
rigorously constructed research for new indications.
PET in public sector hospitals
South Africa has lagged in the practical implementation of 
technological developments. This has been more marked in 
the public sector. Recently the first PET scans in South Africa 
were performed in a private hospital and it is likely that the 
modality will proliferate in other private hospitals. Historically, 
novel imaging modalities have followed a similar pattern in 
South Africa, with initial introduction largely taking place in 
private hospitals. The latter sometimes sold the services to state 
facilities, with the technology only becoming available much 
later in academic hospitals.
   So far it appears that PET is following this pattern. However, 
4 years ago the Department of Health conducted a process of 
‘modernisation of tertiary services’ in South African public 
hospitals. Its objective was to anticipate and put plans in 
place to address the needs of each specialty over the following 
decade. Nuclear medicine and radiology made provision for 
PET in the plans. Increasingly efficient revenue collection is 
now providing the financial means to make the acquisition of 
such equipment possible.
   Having PET initially only available in the private sector 
may not be the most cost-effective way of introducing a 
new technology into the country. A proliferation of private 
facilities may not only be costly to private funders, but the 
provision of services to state hospitals by private facilities is 
also expected to be too costly. It can be argued that the late 
arrival of CT and MRI in the public sector resulted in additional 
costs being incurred. A comprehensive review,7 published in 
2001, of F-18 FDG PET oncology literature documented its 
impressive performance in the diagnosis, staging, re-staging 
and monitoring of therapy for most malignant tumours. This 
should serve as a reminder not to repeat previous mistakes with 
the introduction of PET.
   It needs to be asked whether the absence of public PET 
facilities is appropriate for the training of nuclear medicine 
physicians, radiologists, radiographers, medical physicists, and 
other medical scientists. Until academic hospitals have these 
facilities available, training will have to occur on a piecemeal 
basis at overseas facilities, or within local private facilities. This 
will be less efficient and less effective than when placed within 
the training facility.
   Finally, and perhaps most importantly, the exclusive 
availability of PET in private facilities will not provide equitable 
access to the benefits of this technique by all South Africans.
   The public sector is best positioned to perform much-needed 
research to determine the usefulness of PET in our context. 
The diagnostic sensitivity, specificity and accuracy of a method 
depends in part on the prevalence of diseases, including 
those that may lead to false-positive or false-negative results. 
Therefore an extrapolation of results particularly from high-
income countries to South Africa may be misleading. Locally 
relevant research is required to reconsider the clinical utility of 
the technique, including other applications, and to make the 
necessary adaptations for South Africa. 
   PET is a multidisciplinary modality involving nuclear 
medicine, radiology, oncology, cardiothoracic surgery, general 
surgery, and related disciplines such as radiography, medical 
physics and radiopharmacy. The availability of PET is likely to 
play a crucial role in facilitating the recruitment and retention 
of these personnel in the public sector, thus assisting in 
reducing the brain drain. Because the UK was well behind its 
economic peers in terms of PET availability, a plan for the roll 
out of PET in the UK was drawn up in 2003.8 Although these 
recommendations are unlikely to be wholly applicable to South 
Africa, they provide a useful departure point.
Cost-effectiveness
The cost-effectiveness of any procedure involves measuring 
its cost against its financial impact on patient management. 
For each indication these depend on the local cost of the 
procedure, and the local cost of available alternative diagnostic 
and therapeutic strategies.  While the cost-effectiveness of 
PET in South Africa must be evaluated, a growing literature 
demonstrates that PET is cost-effective for a variety of 
indications and evidence suggests that, used appropriately, 
PET will reduce costs. This may be through the avoidance of 
expensive invasive diagnostic procedures, the minimisation 
of futile surgery, and the early cessation of ineffective 
chemotherapeutic regimens. Studies of lung cancers have 
shown that when PET imaging was done patients being 
assessed for major surgery had their staging changed;9 there 
were major changes in treatment in a significant number of 
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cases, including cancellation of surgery; unnecessary surgery 
was avoided in 1 out of 5 patients with suspected non-small cell 
lung cancer;10,11 and the number of ‘futile’ chest operations was 
halved.9
   Unlike anatomical imaging, PET predicts the efficacy of 
chemotherapeutic regimens early in the course of therapy, 
enabling costly ineffective therapy to be altered early, with 
benefits to patients and costs.12
Conclusion
We welcome the arrival of PET in South Africa, as it will 
undoubtedly contribute to the better care of our patients 
and to the growth of nuclear medicine as a specialty. 
Clinical PET imaging is developing rapidly and many more 
radiopharmaceuticals are being developed to evaluate tumour 
biology, some of which will have advantages over FDG 
in specific clinical situations. Some will be more tumour-
specific with little or no uptake within normal organs, thereby 
increasing the need for the anatomical correlation that 
combined PET/CT provides.
   Accompanying the potential benefits of the arrival of PET 
in South Africa are a number of important challenges that 
need to be met. These include: (i) ensuring equitable access 
to PET for all South Africans; (ii) validation of PET by local 
nuclear medicine facilities, rather than simply extrapolating 
international data; (iii) communicating the strengths and 
weaknesses of PET to oncologists and other clinicians by 
the nuclear medicine community; (iv) reaching consensus 
on guidelines for the local training of nuclear medicine 
physicians, radiologists, radiographers, medical physicists, 
and radiopharmacists; (v) reaching consensus on guidelines for 
the indications of PET studies; and (vi) establishing the role of 
radiology in PET/CT, and achieving co-operation and cross-
education of physicians and technologists.
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